Physician profile

Cynthia Forsthoff

Long Beach, CA

NPI 1841250719

$1,725.26

in general payments reported to CMS, 2019-2025

25 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $284.44 2019
Pfizer INC. $174.58 2019
Astrazeneca Pharmaceuticals LP $149.56 2019
E.R. Squibb & Sons, L.L.C. $146.47 2019
Merck Sharp & Dohme LLC $126.83 2019
Amgen INC. $106.62 2019
Janssen Biotech, INC. $88.32 2019
Incyte Corporation $76.75 2019
Exelixis INC. $73.09 2019
Genentech USA, INC. $63.31 2019
Celgene Corporation $62.47 2019
Gilead Sciences, INC. $45.37 2019
Pharmacyclics LLC, An Abbvie Company $39.85 2019
Abbvie INC. $36.92 2019
Regeneron Healthcare Solutions, INC. $34.06 2019
Show all 25 companies
CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $30.84 2019
Genzyme Corporation $30.11 2019
Takeda Pharmaceuticals U.S.A., INC. $26.70 2019
Seagen INC. $24.24 2019
Amag Pharmaceuticals, INC. $19.04 2019
Tesaro, INC. $18.44 2019
Emd Serono, INC. $18.35 2019
Dova Pharmaceuticals $18.00 2019
Otsuka America Pharmaceutical, INC. $17.39 2019
Clovis Oncology, INC. $13.51 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Cynthia Forsthoff

$1,725.26

in general payments reported 2019-2025

Years
2019
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/129187/cynthia-forsthoff

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.